Graves' Disease Remission Study: MycoMeth Combo

Exclusion Criteria11

• \. Patients with Graves' disease who have undergone treatment or experienced relapse.
• \. Hyperthyroidism due to other etiologies (toxic multinodular goiter, toxic thyroid adenoma, Hashimoto's thyroiditis, subacute thyroiditis, iodine-induced hyperthyroidism, etc.).
• \. Individuals requiring intervention for moderate to severe thyroid eye disease at the time of enrollment.
• \. Patients with hyperthyroidism requiring surgery due to concurrent thyroid cancer.
• \. Those with severe liver or kidney dysfunction (ALT or AST > 3 times the upper limit of normal reference values, blood creatinine > 135 mol/L for males, and 110 mol/L for females).
• \. Individuals with leukopenia (WBC < 3.0×109/L).
• \. Patients with severe heart failure (NYHA class III or IV).
• \. Individuals with chronic or severe infections such as pulmonary tuberculosis, hepatitis B, etc.
• \. Pregnant women, breastfeeding women, those planning pregnancy in the near future, or individuals who cannot comply with contraception during trial.
• \. Participants in or previously involved in other clinical studies.
• \. Individuals unwilling or unable to comply with follow-up or unwilling to participate.